Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» VB-111
VB-111
Gene therapy for ovarian cancer fails PhIII study — sinking VBL Therapeutics' shares
Endpoints
Wed, 07/20/22 - 09:33 am
VBL Therapeutics
gene therapy
ovarian cancer
VB-111
ofra-vec
VBL’s ovarian cancer drug comes though interim phase 3 review
Fierce Biotech
Thu, 08/13/20 - 09:42 am
VBL Therapeutics
clinical trials
VB-111
ovarian cancer
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
Thu, 03/8/18 - 09:39 am
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
Mon, 06/1/15 - 10:06 am
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma